Effect of Add-on Therapy With DLBS3233 on Glycemic Control, Lipid Profile, and Adiponectin in Patients With Type-2 Diabetes Mellitus
Phase of Trial: Phase II/III
Latest Information Update: 24 May 2013
At a glance
- Drugs DLBS 3233 (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.